CF Pharmtech Guangzhou Ltd. and CF Pharmtech Hongkong Ltd. have identified prodrugs of treprostinil reported to be useful for the treatment of pulmonary hypertension and pulmonary fibrosis.
Primelink Biotherapeutics (Shenzhen) Co. Ltd. has synthesized stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer.
Er Stress Research Institute Inc. has disclosed benzothiazoimidazolyl compounds acting as endoplasmic reticulum (ER) stress inhibitors reported to be useful for the treatment of cancer, diabetes, neurodegenerative, autoimmune and metabolic diseases as well as renal, cardiovascular and renal disorders.
Pyrimidine compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors and reported to be useful for the treatment of cancer have been disclosed in a recent Asieris Pharmaceuticals Co. Ltd. patent.
Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the identification of heteroaromatic ring compounds acting as membrane-associated tyrosine-and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Recent Engrail Therapeutics Inc. patents describe new deuterated nemonapride analogues potentially useful for the treatment of depression and schizophrenia.
Novartis AG has synthesized new sodium channel protein type 5 subunit alpha (SCN5A; Nav1.5) blockers reported to be useful for the treatment of heart failure, long QT syndrome, hypertrophic cardiomyopathy, angina pectoris, myotonia, ventricular tachycardia, atrial and ventricular fibrillation, among others.
Tyligand Bioscience Ltd. has prepared and tested tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
While the U.S. Supreme Court sidelined itself over patent issues such as subject matter eligibility, the diagnostic patent wars are still in full swing as a casual review of cases at the U.S. Patent and Trademark Office discloses.
Omniamed Co. Ltd. and Pohang University of Science & Technology have patented compounds acting as nitric oxide (NO) scavengers and reported to be useful for the treatment of cancer, allergy, obesity, myelofibrosis, autoimmune diseases, inflammatory, cardiovascular and neurological disorders, among others.
RSS
